Coastal Infusion Administers Vyvgart® Hytrulo

Vyvgart Hytrulo combines Vivgart (efgartigimod alfa-fcab) with hyaluronidase to treat generalized myasthenia gravis (gMG), a disease that leads to muscle weakness and tiredness and also chronic inflammatory demyelinating polyneuropathy (CIDP). The addition of hyaluronidase forms part of a drug delivery technology called Halozyme's ENHANZE that allows subcutaneous injection of larger volumes of medication.

The active ingredient in Vyvgart Hytrulo, efgartigimod, works by attaching to and blocking the action of a protein called neonatal Fc receptor (FcRn) which is involved in regulating the levels of antibodies in the blood. By blocking FcRn, Vyvgart Hytrulo decreases the level of autoantibodies thereby improving the ability of muscles to contract and reducing the symptoms of the disease and their impact on daily activities.

What It Treats

Vyvgart Hytrulo is used to treat generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).

Prescribed By

Vyvgart Hytrulo is most often prescribed by Neurologists.

How it's Administered

Vyvgart Hytrulo is administered by subcutaneous injection. Vyvgart Hytrulo injections take just a few minutes.

Frequency

Vyvgart Hytrulo is generally administered weekly for 4 weeks.

Related Drugs

Rystiggo, Vyvgart, Zilbrysq

Additional Resources

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies